Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
Status:
Unknown status
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of Pyramax administered for three-day, two-day or one
day, in clearing a P. falciparum infection in asymptomatic carriers.
.